9 results about "Therapy resistant" patented technology

The present disclosure provides methods of identifying a disease or condition suitable for treatment with dupilumab. The present disclosure also provides methods of identifying a subject having a disease or condition suitable for treatment with dupilumab. The present disclosure also provides methods of carrying out a clinical trial for dupilumab treatment of a disease or condition.

The present application relates to the role of UCK1 in promoting the sensitization of colorectal cancer treatment. The present application discloses the key role of UCK1 in the treatment of colorectal cancer. Clinical samples show that the expression of UCK1 in tumor tissues is reduced, and its low expression is related to chemotherapy resistance and poor prognosis. Studies have shown that UCK1 enhances the efficacy of oxaliplatin (OXA) by regulating metabolic pathways, and promotes B cell activation, thereby recruiting CD8 + T cells, and strengthens anti-tumor immunity. UCK1 overexpression can significantly improve OXA sensitivity and produce a synergistic effect with anti-PD-1 therapy. The present application proposes a new strategy centered on activating UCK1, providing a theoretical basis and application prospect for improving the response of colorectal cancer chemotherapy and immunotherapy.

Provided herein are compositions and methods for treating spinal cord injury using nasal administration of anti-CD3 antibodies, e.g., foralumab.

Methods and apparatus disclosed treat pain and mobility impairments by applying controlled subatmospheric pressure to skin over muscle tissue or joints during volitional muscle contractions against adaptive therapist resistance. Domes with basal openings sealing against skin perimeters, are evacuated to 13-90% of atmospheric pressure. Some embodiments have 3-10 second contraction intervals repeated at least three times per subatmospheric treatment cycle, before pressure is ramped to ambient pressure over at least 2 seconds. Results are improved range of motion, muscle strength, and pain reduction. Apparatus embodiments include vacuum manifolds, sensors for pressure and tissue distension, and optional integrated electrodes for performing TENS / STIM.

This invention discloses the application of ferritin heavy chain 1 (FTH1) inhibitors in the preparation of antitumor drugs. This invention collects pre-treatment FFPE tumor tissue from cancer patients receiving anti-PD-1 / L1 therapy. By integrating transcriptomic and proteomic data from baseline samples, FTH1 is screened as a key candidate molecule for immunotherapy resistance. Experiments demonstrate that FTH1 knockout significantly improves the sensitivity of cancer patients to anti-PD-1 / L1 immunotherapy and effectively inhibits tumor growth; conversely, FTH1 overexpression leads to resistance to anti-PD-1 / L1 immunotherapy. This invention can be applied to the development or preparation of antitumor drugs.

The present invention relates to methods for predicting the probability of a treatment response of a human cancer patient to an immune checkpoint blocker treatment e.g. with anti PD-1, and to methods for predicting the probability of survival of a human cancer patient following an immune checkpoint blocker treatment, and to apparatuses and kits which can be used in these methods.

The application discloses an anti-Alzheimer's disease (AD) ultra-small nanodot with high BBB penetration and double targeting, and a preparation method and application thereof, and belongs to the field of nanomaterial preparation and biomedical application. The ultra-small nanodot is obtained by a self-assembly method according to a certain ratio of protein molecules, a five-membered peptide, ferrous ions (Fe 2+ ), and flavonoid drugs. The obtained ultra-small nanodot has the abilities of double targeting, high BBB penetration and multi-target point treatment of AD. Meanwhile, the preparation method is simple, raw materials are easy to obtain, the biological safety is good, the stability is high, the treatment level is various, and the ultra-small nanodot can be rapidly metabolized in a living body, and has the potential to be a safe and efficient multi-target point anti-AD therapeutic agent.

The application belongs to the technical field of biological medicine, and particularly relates to an anti-ACE2 antibody and application thereof. The antibody or antigen binding fragment thereof provided by the application comprises HCDR1, HCDR2 and HCDR3 contained in VH shown in SEQ ID NO:1, and LCDR1, LCDR2 and LCDR3 contained in VL shown in SEQ ID NO:2. The antibody provided by the application can block the combination of the spike protein of all current mutant strains and ACE2 in a broad spectrum without interfering with the enzyme activity of ACE2, and has excellent anti-SARS-CoV-2 treatment effect.